Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
RCT 857 hospitalized patients, showing no significant differences with remdesivir treatment. DISCOVERY trial. EudraCT2020-000936-23, NCT04315948
Ader et al., 9/14/2021, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 17 authors.
risk of death, 6.4% lower, RR 0.94, p = 0.77, treatment 34 of 414 (8.2%), control 37 of 418 (8.9%), adjusted per study, odds ratio converted to relative risk, 28 days.
risk of 7-point scale status, 9.9% lower, RR 0.90, p = 0.39, treatment 414, control 418, 28 days, RR approximated with OR.
risk of 7-point scale status, 2.0% higher, RR 1.02, p = 0.85, treatment 414, control 418, 15 days, RR approximated with OR.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.